P40 (ΔNp63) is more specific than p63 and cytokeratin 5 in identifying squamous cell carcinoma of bronchopulmonary origin: A review and comparative analysis

Diagnostic Cytopathology

Volumn 42, Issue 5, 2014, Pages 453-458

  Vogt, Adam P ^a   Cohen, Cynthia ^a   Siddiqui, Momin T ^a  

^a EMORY UNIVERSITY HOSPITAL   (United States)

Author keywords

cell blocks; immunohistochemistry; P40; squamous cell carcinoma

Indexed keywords

CYTOKERATIN 5; PROTEIN P40; PROTEIN P63; TP63 PROTEIN, HUMAN; TRANSCRIPTION FACTOR; TUMOR MARKER; TUMOR SUPPRESSOR PROTEIN;

ARTICLE; CANCER CELL; COMPARATIVE STUDY; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; FINE NEEDLE ASPIRATION BIOPSY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; PREDICTIVE VALUE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; ADENOCARCINOMA; CARCINOMA, SQUAMOUS CELL; DIFFERENTIAL DIAGNOSIS; FEMALE; GENE EXPRESSION; GENETICS; LUNG; LUNG NEOPLASMS; MALE; MUTATION; PATHOLOGY;

ADENOCARCINOMA; CARCINOMA, SQUAMOUS CELL; DIAGNOSIS, DIFFERENTIAL; FEMALE; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; KERATIN-5; LUNG; LUNG NEOPLASMS; MALE; MUTATION; SENSITIVITY AND SPECIFICITY; TRANSCRIPTION FACTORS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS;

EID: 84899413118     PISSN: 87551039     EISSN: 10970339     Source Type: Journal    
DOI: 10.1002/dc.23045     Document Type: Article

References (27)

1. America Cancer Society. Cancer facts & figures 2012. Atlanta: American Cancer Society; 2012.
2. Adnan H, Rekhtman N, Sigel CS, et al. Advances in fine needle aspiration cytology for the diagnosis of pulmonary carcinoma. Pathol Res Int 2011; 2011: 7, Article ID 897292.
3. Bishop JA, Teruya-Feldstein J, Westra W, et al. p40 (ΔNp63) is superior to p63 for the diagnosis of pulmonary squamous cell carcinoma. Mod Pathol 2012; 25: 405-415.
4. Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010; 363: 1693-1703.
5. Shigematsu H, Lin L, Takahashi T, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 2005; 97: 339-346.
6. Johnson DH, Fehrenbacher L, Novotny, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004; 22: 2184-2191.
7. Hammerman PS, Sos ML, Ramos AH, et al. Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. Cancer Discov 2011; 1; 77-87.
8. Riess JW, Neal JW,. Targeting fibroblast growth factor receptor and discoidin domain receptor 2 in non-small-cell lung cancer. J Thor Oncol; 2012: 7: S385-S386.
9. Weiss J, Sos ML, Seidel D, et al. Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci Transl Med 2010; 2: 62ra93.
10. Travis WD, Brambilla E, Noguchi M, et al. International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 2011; 6: 244-285.
11. Scagliotti G, Brodowicz T, Shepherd FA, et al. Treatment-by-histology interaction analyses in three phase III trials show superiority of pemetrexed in nonsquamous non-small cell lung cancer. J Thorac Oncol 2011; 6: 64-70.
12. Rekhtman N, Ang DC, Sima CS, et al. Immunohistochemical algorithm for differentiation of lung adenocarcinoma and squamous cell carcinoma based on large series of whole-tissue sections with validation in small specimens. Mod Pathol 2011; 24: 1348-1359.
13. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: Non-small cell lung cancer. Version 3.2012.
14. Chu P, Wu E, Weiss LM,. Cytokeratin 7 and cytokeratin 20 expression in epithelial neoplasms: A survey of 435 cases. Mod Pathol 2000; 13: 962-972.
15. Kaufmann O, Fietze E, Mengs J, et al. Value of p63 and cytokeratin 5/6 as immunohistochemical markers for the differential diagnosis of poorly differentiated and undifferentiated carcinomas. Am J Clin Pathol 2001; 116: 823-830.
16. Au NH, Gown AM, Cheang M, et al. P63 expression in lung carcinoma: A tissue microarray study of 408 cases. Appl Immunohistochem Mol Morphol 2004; 12: 240-247.
17. Kargi A, Gurel D, Tuna B, et al. The diagnostic value of TTF-1, CK 5/6, and p63 immunostaining in classification of lung carcinomas. Appl Immunohistochem Mol Morphol 2007; 15: 415-420.
18. Massion PP, Taflan PM, Jamshedur Rahman SM, et al. Significance of p63 amplification and overexpression in lung cancer development and prognosis. Cancer Res 2003; 63: 7113-7121.
19. Sheikh HA, Fuhrer K, Cieply K, Yousem S,. P63 expression in assessment of bronchioloalveolar proliferations of the lung. Mod Pathol 2004; 17: 1134-1140.
20. Pelosi G, Pasini F, Olsen Stenholm C, et al. P63 immunoreactivity in lung cancer: Yet another player in the development of squamous cell carcinomas ? J Pathol 2002; 198: 100-109.
21. Rodig SJ, Mino-Kenudson M, Dacic S, et al. Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. Clin Cancer Res 2009; 15: 5216-5223.
22. Righi L, Graziano P, Fornari A, et al. Immunohistochemical subtyping of nonsmall cell lung cancer not otherwise specified in fine-needle aspiration cytology. Cancer 2011; 117: 3416-3423.
23. Nobre AR, Albergaria A, Scmitt F,. p40: A p63 isoform useful for lung cancer diagnosis-A review of the physiological and pathological role of p63. Acta Cytologica 2013; 57: 1-8.
24. Aviel-Ronen S, Lau SK, Pintile M, et al. Glypican-3 is overexpressed in lung squamous cell carcinoma, but not in adenocarcinoma. Mod Pathol 2008; 21: 817-825.
25. Lin Q, Xiong L, Pan X,. Expression of GPC3 protein and its significance in lung squamous cell carcinoma. Med Oncol 2012; 29: 663-669.
26. Johnson H, Cohen C, Fatima N, et al. Thyroid transcription factor 1 and napsin-A double stain: Utilizing different vendor antibodies for diagnosing lung adenocarcinoma. Acta Cytologica 2012; 56: 596-602.
27. Fatima N, Cohen C, Lawson, et al. Combined double CK5/p63 stain: Useful adjunct test for diagnosing pulmonary squamous cell carcinoma. Diagn Cytopathol 2011; 40: 943-948.